ArticleBlood cancer journal2023

Gemtuzumab ozogamicin plus standard induction hemotherapy improves outcomes of newly diagnosed intermediate cytogenetic risk acute myeloid leukemia.

Hassan Awada et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.